Cancer treatment reviews最新文献

{"title":"Extracellular vesicles and the “six Rs” in radiotherapy","authors":"Isabel Ripoll-Viladomiu ,&nbsp;Adriele Prina-Mello ,&nbsp;Dania Movia ,&nbsp;Laure Marignol","doi":"10.1016/j.ctrv.2024.102799","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102799","url":null,"abstract":"<div><p>Over half of patients with cancer receive radiation therapy during the course of their disease. Decades of radiobiological research have identified 6 parameters affecting the biological response to radiation referred to as the 6 “Rs”: Repair, Radiosensitivity, Repopulation, Redistribution, Reoxygenation, and Reactivation of the anti-tumour immune response. Extracellular Vesicles (EVs) are small membrane-bound particles whose multiple biological functions are increasingly documented. Here we discuss the evidence for a role of EVs in the orchestration of the response of cancer cells to radiotherapy. We highlight that EVs are involved in DNA repair mechanisms, modulation of cellular sensitivity to radiation, and facilitation of tumour repopulation. Moreover, EVs influence tumour reoxygenation dynamics, and play a pivotal role in fostering radioresistance. Last, we examine how EV-related strategies could be translated into novel strategies aimed at enhancing the efficacy of radiation therapy against cancer.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102799"},"PeriodicalIF":9.6,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001270/pdfft?md5=1fcd1093855636af22faf6a577d5ada4&pid=1-s2.0-S0305737224001270-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141542858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials","authors":"Martina Bortolot ,&nbsp;Francesco Cortiula ,&nbsp;Gianpiero Fasola ,&nbsp;Dirk De Ruysscher ,&nbsp;Jarushka Naidoo ,&nbsp;Lizza E.L. Hendriks","doi":"10.1016/j.ctrv.2024.102797","DOIUrl":"10.1016/j.ctrv.2024.102797","url":null,"abstract":"<div><p>Concurrent chemoradiotherapy (cCRT) followed by one year of consolidation durvalumab is the current standard-of-care for patients with unresectable stage III non-small cell lung cancer (NSCLC), of good functional status. However, cCRT and consolidation durvalumab may be challenging to administer for selected patient populations underrepresented or even excluded in clinical trials: older and/or frail patients; those with cardiovascular or respiratory comorbidities in which treatment-related adverse events may be higher, and patients with pre-existing autoimmune disorders for whom immunotherapy use is controversial. In this narrative review, we discuss the current evidence, challenges, ongoing clinical trials and potential future treatment scenarios in relevant subgroups of patients with locally advanced NSCLC, who are underrepresented in clinical trials.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102797"},"PeriodicalIF":9.6,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001257/pdfft?md5=bd395e119d37b50d2a943477b086de1e&pid=1-s2.0-S0305737224001257-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and future perspectives for the use of temozolomide in the treatment of SCLC","authors":"Elisa Andrini ,&nbsp;Gianluca Ricco ,&nbsp;Arianna Zappi ,&nbsp;Serena Aloi ,&nbsp;Mirela Giordano ,&nbsp;Annalisa Altimari ,&nbsp;Elisa Gruppioni ,&nbsp;Thais Maloberti ,&nbsp;Dario de Biase ,&nbsp;Davide Campana ,&nbsp;Giuseppe Lamberti","doi":"10.1016/j.ctrv.2024.102798","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102798","url":null,"abstract":"<div><p>Small-cell lung cancer (SCLC), accounting for 10–20 % of all lung tumors, represents the most aggressive high-grade neuroendocrine carcinoma. Most patients are diagnosed with extensive-stage SCLC (ES-SCLC), with brian metastases identified in ∼ 80 % of cases during the disease cours, and the prognosis is dismal, with a 5-year survival rate of less than 5 %.</p><p>Current available treatments in the second-line setting are limited, and topotecan has long been the only FDA-approved drug in relapsed or refractory ES-SCLC, until the recent approval of lurbinectedin, a selective inhibitor of RNA polymerase II.</p><p>Temozolomide (TMZ) is an oral alkylating agent, which showed single-agent activity in SCLC, particularly among patients with O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation.</p><p>Several studies have revealed the synergistic activity of temozolomide with poly-ADP-ribose polymerase (PARP) inhibitors, that prevent repair of TMZ-induced DNA damage.</p><p>This review focuses on the rationale for the use of TMZ in ES-SCLC and provides an overview of the main trials that have evaluated and are currently investigating its role, both as a single-agent and in combinations, in relapse or refractory disease.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102798"},"PeriodicalIF":9.6,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141542857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological risks associated with the planned watch-and-wait strategy using total neoadjuvant treatment for rectal cancer: A narrative review","authors":"Joanna Socha ,&nbsp;Robert Glynne-Jones ,&nbsp;Krzysztof Bujko","doi":"10.1016/j.ctrv.2024.102796","DOIUrl":"10.1016/j.ctrv.2024.102796","url":null,"abstract":"<div><p>Overall survival benefit of total neoadjuvant treatment (TNT) remains unconfirmed. Thus, in our opinion, the main rationale for using TNT is a planned watch-and-wait (w&amp;w) strategy to improve patients’ long-term quality of life through organ preservation. The OPRA randomized trial, which examined a planned w&amp;w strategy using TNT, showed a higher organ preservation rate but also a higher regrowth rate compared to studies on the opportunistic w&amp;w strategy. Higher rates of complete clinical response with TNT did not improve disease-free survival compared to historical controls. Therefore, the gain in organ-sparing capability might not be balanced by the increased oncological risk. The ultimate local failure rate in the intention-to-treat analysis of the OPRA trial was 13% for induction chemotherapy and 16% for consolidation chemotherapy, which seems higher than expected compared to 8% in a <em>meta</em>-analysis of w&amp;w studies or 12% after TNT and surgery in the PRODIGE-23 and RAPIDO trials, which enrolled patients with more advanced cancers than the OPRA trial. Other studies also suggest worse local control when surgery is delayed for radio–chemoresistant cancers. Our review questions the safety of the planned w&amp;w strategy using TNT in unselected patients. To reduce the oncological risk while maintaining high organ preservation rates, we suggest that the planned w&amp;w strategy using TNT requires a two-tier patient selection process: before treatment and after tumor response assessment at the midpoint of consolidation chemotherapy. These robust selections should identify patients who are unlikely to achieve organ preservation with TNT and would be better managed by preoperative chemoradiotherapy (without consolidation chemotherapy) and surgery, or by discontinuing consolidation chemotherapy and proceeding directly to surgery.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102796"},"PeriodicalIF":9.6,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration","authors":"Jean-Luc Raoul ,&nbsp;Philip D. Hansten","doi":"10.1016/j.ctrv.2024.102794","DOIUrl":"10.1016/j.ctrv.2024.102794","url":null,"abstract":"<div><h3>Background</h3><p>Proton pump inhibitors (PPIs) are widely used in cancer patients despite accumulating data showing that they can impact the efficacy of major anticancer drugs. This is particularly important with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (CPIs).</p></div><div><h3>Results</h3><p>Most TKIs require gastric acidity for their absorption and some retrospective series demonstrated that coprescription decreases the survival benefit of some TKI use (erlotinib, gefitinib and pazopanib). Relations between microbiota, the immune system, and the efficacy of immunotherapy are now obvious, just as modifications to gut flora after PPIs use are well-known. Many retrospective articles, including articles based on individual-participant data from randomized studies, demonstrated that patients treated with CPIs have a poorer outcome (overall survival, progression-free survival and response rate) when they received PPIs concomitantly, while there was no impact of such coprescription among patients in control arms, not treated with immunotherapies. Similar data were also observed in patients treated with palbociclib.</p></div><div><h3>Conclusion</h3><p>For these interactions, it is very important to use the precautionary principle and warn patients and physicians about this. In patients who require acid suppression because of severe symptoms, using antacids or H2 blockers could be recommended.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102794"},"PeriodicalIF":9.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma","authors":"Alexander W. Loftus ,&nbsp;Mehrdad Zarei ,&nbsp;Hanna Kakish ,&nbsp;Omid Hajihassani ,&nbsp;Jonathan J. Hue ,&nbsp;Christina Boutros ,&nbsp;Hallie J. Graor ,&nbsp;Faith Nakazzi ,&nbsp;Tsegaw Bahlibi ,&nbsp;Jordan M. Winter ,&nbsp;Luke D. Rothermel","doi":"10.1016/j.ctrv.2024.102795","DOIUrl":"10.1016/j.ctrv.2024.102795","url":null,"abstract":"<div><p>Melanoma metabolism can be reprogrammed by activating BRAF mutations. These mutations are present in up to 50% of cutaneous melanomas, with the most common being V600E. BRAF mutations augment glycolysis to promote macromolecular synthesis and proliferation. Prior to the development of targeted anti-BRAF therapies, these mutations were associated with accelerated clinical disease in the metastatic setting. Combination BRAF and MEK inhibition is a first line treatment option for locally advanced or metastatic melanoma harboring targetable BRAF mutations. This therapy shows excellent response rates but these responses are not durable, with almost all patients developing resistance. When BRAF mutated melanoma cells are inhibited with targeted therapies the metabolism of those cells also changes. These cells rely less on glycolysis for energy production, and instead shift to a mitochondrial phenotype with upregulated TCA cycle activity and oxidative phosphorylation. An increased dependence on glutamine utilization is exhibited to support TCA cycle substrates in this metabolic rewiring of BRAF mutated melanoma. Herein we describe the relevant core metabolic pathways modulated by BRAF inhibition. These adaptive pathways represent vulnerabilities that could be targeted to overcome resistance to BRAF inhibitors. This review evaluates current and future therapeutic strategies that target metabolic reprogramming in melanoma cells, particularly in response to BRAF inhibition.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102795"},"PeriodicalIF":9.6,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral T-cell lymphoma: From biology to practice to the future","authors":"Owen A. O'Connor ,&nbsp;Helen Ma ,&nbsp;Jason Yong Sheng Chan ,&nbsp;Seok Jin Kim ,&nbsp;Sang Eun Yoon ,&nbsp;Won Seog Kim","doi":"10.1016/j.ctrv.2024.102793","DOIUrl":"10.1016/j.ctrv.2024.102793","url":null,"abstract":"<div><p>Recent advancements in comprehending peripheral T-cell lymphomas (PTCLs) validate and broaden our perspective, highlighting their diverse nature and the varying molecular mechanisms underlying the entities. Based on a comprehensive accumulated understanding, the PTCLs currently overcome the most challenging features of any disease: rarity, incredible heterogeneity, and a lack of any established standard of care. The treatments deployed in the front-line are extrapolated from regimens developed for other diseases. The recent approval of the three drugs brentuximab vedotin (BV), pralatrexate, and belinostat for patients with relapsed or refractory disease has provided clues about pathophysiology and future directions, though challenges satisfying post-marketing requirements (PMR) for those accelerated approvals have led to one of those drugs being withdrawn and put the other two in jeopardy. Edits of the front-line regimens, often called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-plus approaches, look more like CHOP-minus strategies, as the toxicity of five-drug regimens often reduces the dose intensity of the added ‘novel’ drug, nullifying any hope of an advance. The turmoil in the field produced by the aforementioned, coupled with an ever-changing classification, has left the field uncertain about the path forward. Despite these challenges, empiric findings from studies of novel drug approaches, coupled with a logic emerging from studies of PTCL lymphomagenesis, have begun to illuminate, albeit faintly for some, a potential direction. The empiric finding that drugs targeting the discrete components of the PTCL epigenome, coupled with the description of multiple mutations in genes that govern epigenetic biology, offers, at the very least, an opportunity to finally be hypothesis-driven. The most recent recognition that the only combination of drugs shown to markedly improve progression-free survival (PFS) in patients with relapsed disease is one based on dual targeting of different and discrete components of that epigenetic biology has established a possibility that circumnavigating chemotherapy addition studies is both plausible, feasible, and likely the best prospect for a quantum advance in this disease. Herein, we analyze PTCL through a 2025 lens, highlighting and underscoring walls that have impeded progress. We will critically explore all the clues and the panoramic view of PTCL research.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102793"},"PeriodicalIF":9.6,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review","authors":"Janet Brown ,&nbsp;Daniele Santini ,&nbsp;Natalie Charnley ,&nbsp;Alessia Ogareva ,&nbsp;Alison Chisholm ,&nbsp;Robert Jones","doi":"10.1016/j.ctrv.2024.102792","DOIUrl":"10.1016/j.ctrv.2024.102792","url":null,"abstract":"<div><h3>Introduction</h3><p>Bone metastases negatively affect prognosis in patients with advanced renal cell carcinoma (aRCC). We conducted a systematic literature review to identify clinical trial publications including patients with aRCC with and without bone metastases.</p></div><div><h3>Methods</h3><p>The review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta‑Analyses (PRISMA) guidelines and registered with PROSPERO (CRD42022355436). MEDLINE and Embase databases were searched (September 2, 2022) to identify publications reporting efficacy and safety outcomes for patients with/without bone metastasis from clinical trials of systemic RCC therapies. Risk of bias was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE).</p></div><div><h3>Results</h3><p>Of 526 publications screened, 19 were eligible: seven (from five studies) reported phase 3 trials, six reported phase 2 trials, one reported phase 1b/2 trials, and five were pooled analyses. Five publications reported moderate-quality evidence, while 14 were graded as low- or very low-quality evidence, suggesting a high potential for uncertainty. Five studies reported benefits of investigational therapies versus comparators in patients with and without bone metastases; these studies included cabozantinib, nivolumab, cabozantinib plus nivolumab, and lenvatinib plus pembrolizumab treatment arms. Data were also available for nivolumab plus ipilimumab. Bone metastases were consistently associated with poor prognosis in patients with aRCC. Preliminary data support the hypothesis that therapies targeting pathways implicated in the development of bone metastases may be beneficial, and warrant further investigation. However, data to support treatment decision-making are lacking.</p></div><div><h3>Conclusion</h3><p>Our findings highlight the need for clinical data to assist in defining the optimal treatment for patients with aRCC and bone metastasis.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102792"},"PeriodicalIF":9.6,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001208/pdfft?md5=a1bea8e56da6649d0b21f2879b6546af&pid=1-s2.0-S0305737224001208-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer","authors":"Arianna Marinello ,&nbsp;Marco Tagliamento ,&nbsp;Arianna Pagliaro ,&nbsp;Nicole Conci ,&nbsp;Eugenia Cella ,&nbsp;Damien Vasseur ,&nbsp;Jordi Remon ,&nbsp;Antonin Levy ,&nbsp;Filippo Gustavo Dall’Olio ,&nbsp;Benjamin Besse","doi":"10.1016/j.ctrv.2024.102791","DOIUrl":"10.1016/j.ctrv.2024.102791","url":null,"abstract":"<div><p>Liquid biopsy is a minimally invasive method for biomarkers detection in body fluids, particularly in blood, which offers an elevated and growing number of clinical applications in oncology. As a result of the improvement in the techniques for DNA analysis, above all next-generation sequencing (NGS) assays, circulating tumor DNA (ctDNA) has become the most informing tumor-derived material for most types of cancer, including non-small cell lung cancer (NSCLC). Although ctDNA concentration is higher in patients with advanced tumors, it can be detected even in patients with early-stage disease. Therefore, numerous clinical applications of ctDNA in the management of early-stage lung cancer are emerging, such as lung cancer screening, the identification of minimal residual disease (MRD), and the prediction of relapse before radiologic progression. Moreover, a high number of clinical trials are ongoing to better define the impact of ctDNA evaluation in this setting. Aim of this review is to offer a comprehensive overview of the most relevant implementations in using ctDNA for the management of early-stage lung cancer, addressing available data, technical aspects, limitations, and future perspectives.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102791"},"PeriodicalIF":9.6,"publicationDate":"2024-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001191/pdfft?md5=d93b0824ae5952be20c59f8849b43f4e&pid=1-s2.0-S0305737224001191-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locally advanced and metastatic endometrial cancer: Current and emerging therapies","authors":"Alixe Salmon ,&nbsp;Alizée Lebeau ,&nbsp;Sylvie Streel ,&nbsp;Adriane Dheur ,&nbsp;Sophie Schoenen ,&nbsp;Frédéric Goffin ,&nbsp;Elodie Gonne ,&nbsp;Frédéric Kridelka ,&nbsp;Athanasios Kakkos ,&nbsp;Christine Gennigens","doi":"10.1016/j.ctrv.2024.102790","DOIUrl":"10.1016/j.ctrv.2024.102790","url":null,"abstract":"<div><p>Until recently, patients diagnosed with locally advanced and metastatic endometrial cancer faced significant challenges in their treatment due to limited options and poor prognostic outcomes. The sequencing of tumors has been a major advancement in its management. It has led to The Cancer Genome Atlas classification currently used in clinical practice and the initiation of several clinical trials for innovative treatments targeting principally signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism. Numerous clinical trials are investigating a combinatorial approach of these targeted therapies to counter tumoral resistance, cellular compensatory mechanisms, and tumor polyclonality. This review provides a comprehensive overview of historical, current, and promising therapies in advanced and metastatic endometrial cancer. It particularly highlights clinical research on targeted and hormonal therapies, but also immunotherapy, reflecting the evolving landscape of treatment modalities for this disease.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102790"},"PeriodicalIF":9.6,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S030573722400118X/pdfft?md5=3bf268b0dc2458654b3722f96e126023&pid=1-s2.0-S030573722400118X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}